Johnson Matthey partners with Immunomedics to develop life- saving cancer treatment.

Johnson Matthey (LSE: JMAT), a global leader in science that enables a cleaner and healthier world, announced a strategic manufacturing partnership for the large-scale production of the drug-linker used in Immunomedics’ lead antibody-drug conjugate.

The antibody-drug conjugate, sacituzumab govitecan, is a treatment for patients with metastatic triple-negative breast cancer, currently under priority review by the FDA for accelerated approval. If approved, sacituzumab govitecan would be the first therapy approved for this patient group.

The drug-linker CL2A-SN-38 is a critical component in the novel antibody-drug conjugate. This key constituent is being produced at JM’s Devens, MA facility. Immunomedics has significantly scaled the ongoing partnership due to JM’s track-record in high potency GMP manufacturing and proven chemical and analytical development for scale-up and production of complex molecules.

“We are proud to build on our existing relationship with Immunomedics to enable the production of viable treatment options to improve cancer patients’ lives,” said Nick Shackley, Vice President, Health. “This long-term master supply agreement signifies our continuing dedication to help companies deliver novel treatments and medicines, to create a healthier world.”

About Johnson Matthey

Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200-years of sustained commitment to innovation and technological breakthroughs that improve the function, performance and safety of our customer’s products. Our science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources. Today more than 13,000 Johnson Matthey professionals collaborate with our network of customers and partners to make a real difference to the world around us. For more information, visit www.matthey.com

Inspiring science, enhancing life

About Sacituzumab Govitecan

Sacituzumab govitecan, Immunomedics’ most advanced product candidate, is a novel, first-in-class antibody-drug conjugate. It is currently under priority review by the U.S. Food and Drug Administration for accelerated approval as a treatment of patients with metastatic triple-negative breast cancer who have received two prior therapies for metastatic disease. If approved, sacituzumab govitecan would be the first therapy approved for patients with metastatic triple-negative breast cancer.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at https://immunomedics.com/. The information on its website does not, however, form a part of this press release.

Media enquiries:

For more information regarding JM, contact:

Pranika Sivakumar Notch Communications +44(0) 161 457 7230

pranika.sivakumar@notchcommunications.co.uk